{
  "first_published_at": "2009-01-01", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON088141", 
  "title": "Piperacillin/tazobactam: compatibility of generics differs from brand leader (Tazocin)", 
  "tags": "{\"parsed_therapeutic\": [\"infectious-disease\"], \"Audience:\": [\"Secondary care\"], \"Therapeutic area:\": [\"Infectious disease\"]}", 
  "_document_number": 276, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/dose_icon.png", 
  "therapeutic_area": [
    "infectious-disease"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Piperacillin/tazobactam: compatibility of generics differs from brand leader (Tazocin)</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: January 2009</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!---->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div id=\"dsuSynopsis\" class=\"yellow\">\r\n\t\t\t\t\t\t\t\t\t<div class=\"dsuArticlePadding\">\r\n\t\t\t\t\t\t\t\t\t<span id=\"dsuSynopsisTitle\"><b>Summary</b></span>\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<br>Generic piperacillin/tazobactam products have different compatibilities with other medicines compared with Tazocin, raising a risk of serious medication errors. Generic piperacillin/tazobactam must not be mixed or co-administered with any aminoglycoside, and must not be reconstituted or diluted with lactated Ringer&#8217;s (Hartmann&#8217;s) solution<br>\t\r\n\t\t\t\t\t\t\t\t\t</div>         \t\t\r\n\t\t\t\t\t\t\t\t\t<div id=\"dsuSynopsisCut\">\r\n\t\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p>Piperacillin/tazobactam is licensed for the treatment of a wide range of infections. In addition to the brand leader (called <strong>Tazocin</strong>, which was reformulated in 2008), generic formulations are now available.</p><p>Generic piperacillin/tazobactam products have different compatibilities with other medicines compared with Tazocin, raising a risk of serious medication errors.</p><div class=\"dull_highlight\">\r\n\t\t\t<p><strong>Advice for healthcare professionals:</strong></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>Generic piperacillin/tazobactam must <strong>not</strong> be mixed or co-administered with any aminoglycoside, and must <strong>not</strong> be reconstituted or diluted with lactated Ringer&rsquo;s (Hartmann&rsquo;s) solution</li>\r\n\t\t\t\t<li>Pharmacists should clearly label reconstituted generic piperacillin/tazobactam with a statement that the product must not be mixed or coadministered with aminoglycosides</li>\r\n\t\t\t\t<li>Prescription charts should be checked to ensure that where patients are prescribed both aminoglycosides and generic piperacillin/tazobactam these are not administered at the same time because this can lead to inactivation of the aminoglycoside. Clinical and nursing staff should be advised of the risks with these products</li>\r\n\t\t\t\t<li>Generic piperacillin/tazobactam is <strong>not</strong> compatible with lactated Ringer&rsquo;s (Hartmann&rsquo;s) solution</li>\r\n\t\t\t\t<li>If you are in doubt about which piperacillin/tazobactam medicine is in use, contact a hospital pharmacist before reconstitution or administration</li>\r\n\t\t\t</ul></div><p>Marketing authorisation holders for generic piperacillin/tazobactam are providing educational materials for healthcare professionals, including: guidance for pharmacists; posters for display in pharmacy-run CIVAS (Centralised Intravenous Additive Service) units; posters for display in nursing and clinical areas; and a training pack for all professionals who have a role in the supply and administration of these medicines.</p><p>Please remember that you can report suspected adverse events to medicines using a <a href=\"http://www.yellowcard.gov.uk\" target=\"_blank\">Yellow Card</a>.</p><p>For information about the <a href=\"ssLINK/CON084776\" target=\"_blank\" title=\"reformulation of Tazocin\">reformulation of Tazocin</a>, see Drug Safety Update article published March 2008.</p><p><em>Article citation: Drug Safety Update January 2009, vol 2 issue 6: 2.</em></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p>Piperacillin/tazobactam is licensed for the treatment of a wide range of infections. In addition to the brand leader (called <strong>Tazocin</strong>, which was reformulated in 2008), generic formulations are now available.</p><p>Generic piperacillin/tazobactam products have different compatibilities with other medicines compared with Tazocin, raising a risk of serious medication errors.</p><div class=\"dull_highlight\">\r\n\t\t\t<p><strong>Advice for healthcare professionals:</strong></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>Generic piperacillin/tazobactam must <strong>not</strong> be mixed or co-administered with any aminoglycoside, and must <strong>not</strong> be reconstituted or diluted with lactated Ringer&#8217;s (Hartmann&#8217;s) solution</li>\r\n\t\t\t\t<li>Pharmacists should clearly label reconstituted generic piperacillin/tazobactam with a statement that the product must not be mixed or coadministered with aminoglycosides</li>\r\n\t\t\t\t<li>Prescription charts should be checked to ensure that where patients are prescribed both aminoglycosides and generic piperacillin/tazobactam these are not administered at the same time because this can lead to inactivation of the aminoglycoside. Clinical and nursing staff should be advised of the risks with these products</li>\r\n\t\t\t\t<li>Generic piperacillin/tazobactam is <strong>not</strong> compatible with lactated Ringer&#8217;s (Hartmann&#8217;s) solution</li>\r\n\t\t\t\t<li>If you are in doubt about which piperacillin/tazobactam medicine is in use, contact a hospital pharmacist before reconstitution or administration</li>\r\n\t\t\t</ul></div><p>Marketing authorisation holders for generic piperacillin/tazobactam are providing educational materials for healthcare professionals, including: guidance for pharmacists; posters for display in pharmacy-run CIVAS (Centralised Intravenous Additive Service) units; posters for display in nursing and clinical areas; and a training pack for all professionals who have a role in the supply and administration of these medicines.</p><p>Please remember that you can report suspected adverse events to medicines using a <a href=\"http://www.yellowcard.gov.uk\" target=\"_blank\">Yellow Card</a>.</p><p>For information about the <a href=\"http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/ssLINK/CON084776\" target=\"_blank\" title=\"reformulation of Tazocin\">reformulation of Tazocin</a>, see Drug Safety Update article published March 2008.</p><p><em>Article citation: Drug Safety Update January 2009, vol 2 issue 6: 2.</em></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2009-01-01", 
  "date_last_modified": "2010-08-16", 
  "_assets": [], 
  "_item_id": 276, 
  "summary": "Generic piperacillin/tazobactam products have different compatibilities with other medicines compared with Tazocin, raising a risk of serious medication errors. Generic piperacillin/tazobactam must not be mixed or co-administered with any aminoglycoside, and must not be reconstituted or diluted with lactated Ringer’s (Hartmann’s) solution", 
  "body": "Article date: January 2009\n\nPiperacillin/tazobactam is licensed for the treatment of a wide range of infections. In addition to the brand leader (called Tazocin, which was reformulated in 2008), generic formulations are now available.\n\nGeneric piperacillin/tazobactam products have different compatibilities with other medicines compared with Tazocin, raising a risk of serious medication errors.\n\nAdvice for healthcare professionals:  \n  \n  * Generic piperacillin/tazobactam must not be mixed or co-administered with any aminoglycoside, and must not be reconstituted or diluted with lactated Ringer’s (Hartmann’s) solution  \n  * Pharmacists should clearly label reconstituted generic piperacillin/tazobactam with a statement that the product must not be mixed or coadministered with aminoglycosides  \n  * Prescription charts should be checked to ensure that where patients are prescribed both aminoglycosides and generic piperacillin/tazobactam these are not administered at the same time because this can lead to inactivation of the aminoglycoside. Clinical and nursing staff should be advised of the risks with these products  \n  * Generic piperacillin/tazobactam is not compatible with lactated Ringer’s (Hartmann’s) solution  \n  * If you are in doubt about which piperacillin/tazobactam medicine is in use, contact a hospital pharmacist before reconstitution or administration  \n  \nMarketing authorisation holders for generic piperacillin/tazobactam are providing educational materials for healthcare professionals, including: guidance for pharmacists; posters for display in pharmacy-run CIVAS (Centralised Intravenous Additive Service) units; posters for display in nursing and clinical areas; and a training pack for all professionals who have a role in the supply and administration of these medicines.\n\nPlease remember that you can report suspected adverse events to medicines using a [Yellow Card](http://www.yellowcard.gov.uk).\n\nFor information about the [reformulation of Tazocin](http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/ssLINK/CON084776), see Drug Safety Update article published March 2008.\n\nArticle citation: Drug Safety Update January 2009, vol 2 issue 6: 2.\n"
}